News - Mergers & Acquisitions, Oncology, Immunologicals

Resverlogix to spin-out RVX Thera to unlock epigenetics platform value

10-04-2013

Canadian drugmaker Resverlogix (TSX:RVX), which is exploring a sale, says that its board of directors…

ApolipoproteinBiotechnologyImmunologicalsMergers & AcquisitionsOncologyResverlogixRVX TherapeuticsRVX-208

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

Back to top